Treatment of necrobiosis lipoidica with the tumor necrosis factor antagonist etanercept - 09/08/11
Doi : 10.1016/j.jaad.2005.11.1042
Joshua A. Zeichner, MD, Dana W.K. Stern, MD, Mark Lebwohl, MD ⁎ 
Mount Sinai Medical Center, New York, NY
Correspondence to: Mark Lebwohl, MD, Department of Dermatology, Mount Sinai Medical Center, 5 East 98 St, 5th Flr, Box 1048, New York, NY 10029Plan
| This case report was investigator initiated. Financial support for the manuscript was provided by Amgen Inc and by Wyeth Research. Conflicts of interest: Dr Zeichner has served as a clinical investigator for Amgen, Biogen, IDEC, and Abbott Laboratories. Dr Lebwohl received an honorarium for this manuscript, and is a consultant (or has pending consulting agreements) for Abbott, Amgen, Biogen, Centocor, Genentech, Novartis, and Warner Chilcott. In the last 12 months, Dr Lebwohl also has served as a speaker for Abbott, Amgen, Biogen, Connetics, Fujisawa, Galderma, and Genentech. In the past 12 months, members of Dr Lebwohl’s department have served as investigators for Abbott, Allergan, Amgen, Biogen, Centocor, Connetics, Fujisawa, Genentech, and Novartis. Reprints not available from the authors. |
© 2006
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 54 - N° 3S2
P. S120-S121 - mars 2006 Retour au numéro
Article précédent
- What have we learned in dermatology from the biologic therapies?
- Brian J. Nickoloff, Seth R. Stevens
- Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept
- Paul S. Yamauchi, Nicholas J. Lowe, Vivian Gindi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?